Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Medtronic
McKinsey
Dow
McKesson

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,811,794

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,811,794 protect, and when does it expire?

Patent 6,811,794 protects INTUNIV and is included in one NDA.

Protection for INTUNIV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,811,794
Title: Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
Abstract:A pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5. Such compositions have minimized pH-dependent dissolution profiles or pH-independent dissolution profiles.
Inventor(s): Burnside; Beth A. (Bethesda, MD), Chang; Rong-Kun (Rockville, MD), Guo; Xiaodi (New City, NY)
Assignee: Shire Laboratories, Inc. (Rockville, MD)
Application Number:10/027,349
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,811,794
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Dosage form;

Drugs Protected by US Patent 6,811,794

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Shire INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037-001 Sep 2, 2009 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Shire INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037-002 Sep 2, 2009 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Shire INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037-003 Sep 2, 2009 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Shire INTUNIV guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022037-004 Sep 2, 2009 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
McKesson
Harvard Business School
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.